Advances in systemic antifungal therapy

Clinics in Dermatology

Volumn 30, Issue 6, 2012, Pages 657-661

  Stevens, David A ^a,b,c  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; BENZODIAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CASPOFUNGIN; CIMETIDINE; CYCLOSPORIN; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; QUINIDINE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ACNE; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; BLASTOMYCOSIS; CANDIDIASIS; COCCIDIOIDOMYCOSIS; COMBINATION CHEMOTHERAPY; CRYPTOCOCCOSIS; DERMATITIS; DERMATOMYCOSIS; DIARRHEA; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; ERYTHEMA; ESOPHAGUS CANDIDIASIS; FOOD DRUG INTERACTION; FUSARIOSIS; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; HISTOPLASMOSIS; HOT FLUSH; HUMAN; HYPOKALEMIA; HYPOTENSION; INFECTION PREVENTION; INVASIVE CANDIDIASIS; LIVER FUNCTION; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; PHAEOHYPHOMYCOSIS; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; PSEUDALLESCHERIASIS; SIDE EFFECT; SOUTH AMERICAN BLASTOMYCOSIS; SPOROTRICHOSIS; SYSTEMIC MYCOSIS; SYSTEMIC THERAPY; THRUSH; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA; VAGINA CANDIDIASIS;

ANTIFUNGAL AGENTS; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZOLES;

EID: 84867607134     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2011.09.018     Document Type: Article

References (76)

1. Wong-Beringer A., Jacobs R.A., Guglielmo B.J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998, 27:603-618.
2. Antoniadou A. Dupont B. Lipid formulations of amphotericin B: Where are we today?. J Mycol Med 2005, 15:230-238.
3. Francis P., Walsh T.J. Evolving role of flucytosine in immunocompromised patients-new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992, 15:1003-1018.
4. Dismukes W.E., Cloud G., Gallis H.A., et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987, 317:334-341.
5. Stevens D.A. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999, 19:603-611.
6. Stevens D.A., Lee J.Y. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997, 157:1857-1862.
7. Stevens D.A., Schwartz H.J., Lee J.Y., et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000, 342:756-762.
8. Galgiani J.N., Cloud G.A., Catanzaro A., et al. A comparison of oral fluconazole or itraconazole for progressive, nonmeningeal coccidioidomycosis. Ann Intern Med 2000, 133:676-686.
9. Mangino J.E., Pappas P.G. Itraconazole for the treatment of histoplasmosis and blastomycosis. Int J Antimicrob Ag 1995, 5:219-225.
10. Sharkey-Mathis P.K., Kauffman C.A., Graybill J.R., et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993, 95:279-285.
11. Van Hecke E., Van Cutsem J. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea pedis and tinea manuum. Mycoses 1988, 31:641-649.
12. Morgenstern G.R., Prentice A.G., Prentice H.G., et al. A randomised controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999, 105:901-911.
13. Nucci M., Biasoli I., Akiti T., et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000, 30:300-305.
14. Menichetti F., Del Favero A., Martino P., et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1999, 28:250-255.
15. Boogaerts M., Winston D.J., Bow E.J., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001, 135:412-422.
16. Wilcox C.M., Darouiche R.O., Laine L., et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997, 176:227-232.
17. Graybill J.R., Vazquez J., Darouiche R.O., et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998, 104:33-39.
18. Zervos M., Meunier F. Fluconazole (Diflucan): a review. Int J Antimicrob Ag 1993, 3:147-170.
19. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994, 331:1325-1330.
20. Rex J.H., Pappas P.G., Karchmer A.W., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221-1228.
21. Saag M.S., Powderly W.G., Cloud G.A., et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992, 326:83-89.
22. Van der Horst C.M., Saag M.S., Cloud G.A., et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997, 337:15-21.
23. Powderly W.G., Saag M.S., Cloud G.A., et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992, 326:793-798.
24. Haubrich R.H., Haghighat D., Bozzette S.A., et al. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis 1994, 170:238-242.
25. Diaz M., Negroni R., Montero-Gei F., et al. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. Clin Infect Dis 1992, 14(Suppl 1):S68-S76.
26. Catanzaro A., Galgiani J.N., Levine B.E., et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med 1995, 98:249-256.
27. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326:845-851.
28. Slavin M.A., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995, 171:1545-1552.
29. Menichetti F., Del Favero A., Martino P., et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 1994, 120:913-918.
30. Winston D.J., Chandrasekar P.H., Lazarus H.M., et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993, 118:495-503.
31. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000, 96:2055-2061.
32. Wingard J.R., Merz W.G., Rinaldi M.G., et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991, 325:1274-1277.
33. Wingard J.R., Merz W.G., Rinaldi M.G., et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993, 37:1847-1849.
34. Castro L.G.M., Belda W., Cucé L.C., et al. Successful treatment of sporotrichosis with oral fluconazole: a report of three cases. Br J Dermatol 1993, 128:352-356.
35. Donnelly J.P., DePauw B.E. Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. Clinical Microbiol Infect 2004, 10(Suppl 1):107-117.
36. Muijsers R.B.R., Goa K.L., Scott L.J. Voriconazole in the treatment of invasive aspergillosis. Drugs 2002, 62:2655-2665.
37. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
38. Denning D.W., Ribaud P., Milpied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563-571.
39. Perfect J.R., Marr K.A., Walsh T.J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122-1131.
40. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-234.
41. Deresinski S.C., Stevens D.A. Caspofungin. Clin Infect Dis 2003, 36:1445-1457.
42. Kurtz M.B., Rex J.H. Glucan synthase inhibitors as antifungal agents. Advances In Protein Chemistry 2001, 56:463-475.
43. Denning D.W. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002, 49:889-891.
44. Bennett J.E. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006, 355:1154-1159.
45. Cappelletty D., Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007, 27:369-388.
46. Mora-Duarte J., Betts R., Rotstein R., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029.
47. Villanueva A., Gotuzzo E., Arathoon E., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002, 113:294-299.
48. Kartsonis N., DiNubile M.J., Bartizal K., et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acq Immune Defic Syndrome Hum Retrovirol 2002, 31:183-187.
49. Espinel-Ingroff A.V. SCH56592. Current Opin Anti-infective Drugs 1997, 1:377-384.
50. Nagappan V., Deresinski S. Reviews of anti-infective agents: Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007, 45:1610-1617.
51. Ezzet F., Wexler D., Courtney R., et al. Oral bioavailability of posaconazole in fasted healthy subjects-comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005, 44:211-220.
52. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2-12.
53. Raad I.I., Graybill J.R., Bustamante A.B., et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006, 42:1726-1734.
54. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft- versus-host disease. N Engl J Med 2007, 356:335-347.
55. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348-359.
56. Stevens D.A., Rendon A., Gaona-Flores V., et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007, 132:952-958.
57. Vazquez J.A., Skiest D.J., Tissot-Dupont H., et al. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials 2007, 8:86-97.
58. Raad I.I., Hachem R.Y., Herbrecht R., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006, 42:1398-1403.
59. Hope W.W., Seibel N.L., Schwartz C.L., et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007, 51:3714-3719.
60. Wiederhold N.P., Lewis J.S. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 2007, 8:1155-1166.
61. Pappas P.G., Rotstein C.M.F., Betts R.F., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
62. Kuse E.R., Chetchotisakd P., da Cunha C.A., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527.
63. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005, 24:654-661.
64. de Wet N.T.E., Bester A.J., Viljoen J.J., et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Therapeut 2005, 21:899-907.
65. de Wet N., Llanos-Cuentas A., Suleiman J., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004, 39:842-849.
66. Hiemenz J., Cagnoni P., Simpson D., et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005, 49:1331-1336.
67. Sirohi B., Powles R.L., Chopra R., et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006, 38:47-51.
68. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39:1407-1416.
69. Denning D.W., Marr K.A., Lau W.M., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infection 2006, 53:337-349.
70. Benjamin D.K., Driscoll T., Seibel N.L., et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006, 50:632-638.
71. Vazquez J.A., Sobel J.D. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006, 43:215-222.
72. Vehreschild J.J., Kummerle T., Karthaus M., et al. Anidulafungin-state of affairs from a clinical perspective. Mycoses 2007, 50:38-43.
73. Krause D.S., Reinhardt J., Vazquez J.A., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004, 48:2021-2024.
74. Reboli A.C., Rotstein C., Pappas P.G., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482.
75. van Asbeck E., Clemons K.V., Stevens D.A. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing, and antimicrobial susceptibility. Crit Rev Microbiol 2009, 35:283-309.
76. Mukherjee P.K., Sheehan D.J., Hitchcock C.A., et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005, 18:163-194.